Updating results

410 results

Sort: Relevance | Date

Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355

In development [GID-TA10321] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

In development [GID-TA10165] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]

In development [GID-TAG410] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46]

In development [GID-TAG405] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

In development [GID-TAG406] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (brain metastases) - etirinotecan pegol [ID881]

In development [GID-TA10066] Expected publication date: TBC

Technology appraisal guidance In development

Clostridium difficile associated diarrhoea - tolevamer [ID378]

In development [GID-TAG389] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

In development [GID-TA10148] Expected publication date: TBC

Technology appraisal guidance In development

Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]

In development [GID-TAG369] Expected publication date: TBC

Technology appraisal guidance In development

Head and neck cancer - contusugene ladenovec [ID76]

In development [GID-TAG407] Expected publication date: TBC

Technology appraisal guidance In development

Renal cell carcinoma (second line metastatic) - pazopanib [ID70]

In development [GID-TAG398] Expected publication date: 01 January 2011

Technology appraisal guidance In development

Pacritinib for treating myelofibrosis [ID880]

In development [GID-TA10133] Expected publication date: TBC

Technology appraisal guidance In development

Osteoarthritis - naproxcinod [ID417]

In development [GID-TAG426] Expected publication date: TBC

Technology appraisal guidance In development

Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

In development [GID-TA10154] Expected publication date: TBC

Technology appraisal guidance In development

Kidney transplantation (rejection) - belatacept [ID87]

In development [GID-TAG239] Expected publication date: TBC

Technology appraisal guidance In development

Venous thromboembolism - apixaban (acute medical illness) [ID310]

In development [GID-TAG419] Expected publication date: TBC

Technology appraisal guidance In development

Hypercholesterolemia - mipomersen [ID524]

In development [GID-TAG437] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]

In development [GID-TAG404] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small cell) - afatinib [ID357]

In development [GID-TAG422] Expected publication date: TBC

Technology appraisal guidance In development

Thrombophilia [ID393]

In development [GID-TAG374] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]

In development [GID-TA10158] Expected publication date: TBC

Technology appraisal guidance In development

Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

In development [GID-TAG332] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]

In development [GID-TA10228] Expected publication date: TBC

Technology appraisal guidance In development

NBTXR-3 for treating soft tissue sarcoma [ID1050]

In development [GID-TA10226] Expected publication date: TBC

Technology appraisal guidance In development

Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270

In development [GID-TA10211] Expected publication date: TBC

Technology appraisal guidance In development

Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies ID1288

In development [GID-TA10212] Expected publication date: TBC

Technology appraisal guidance In development

Plitidepsin in combination with dexamethasone for treating relapsed or refractory multiple myeloma [ID1081]

In development [GID-TA10171] Expected publication date: TBC

Technology appraisal guidance In development

NGR-TNF for previously treated advanced malignant pleural mesothelioma (ID655)

In development [GID-TA10183] Expected publication date: TBC

Technology appraisal guidance In development

Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

In development [GID-TA10180] Expected publication date: TBC

Technology appraisal guidance In development

Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

In development [GID-TA10177] Expected publication date: TBC

Technology appraisal guidance In development

Eculizumab for treating refractory myasthenia gravis [ID1064]

In development [GID-TA10176] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated multiple myeloma (ID1139)

In development [GID-TA10193] Expected publication date: TBC

Technology appraisal guidance In development

Juvenile idiopathic arthritis - adalimumab [ID385]

In development [GID-TAG400] Expected publication date: TBC

Technology appraisal guidance In development

Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

In development [GID-TAG385] Expected publication date: TBC

Technology appraisal guidance In development

Clinically isolated syndrome - beta interferons and glatiramer acetate [ID109]

In development [GID-TAG415] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - idraparinux sodium [ID375]

In development [GID-TAG383] Expected publication date: TBC

Technology appraisal guidance In development

Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]

In development [GID-TA10121] Expected publication date: TBC

Technology appraisal guidance In development

Heart failure (acute decompensated) - nesiritide [ID384]

In development [GID-TAG376] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58]

In development [GID-TAG391] Expected publication date: TBC

Technology appraisal guidance In development

Diabetic retinopathy - ruboxistaurin [ID382]

In development [GID-TAG386] Expected publication date: TBC

Technology appraisal guidance In development

Binimetinib for treating melanoma [ID833]

In development [GID-TA10074] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]

In development [GID-TA10028] Expected publication date: TBC

Technology appraisal guidance In development

Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

In development [GID-TA10033] Expected publication date: TBC

Technology appraisal guidance In development

Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415]

In development [GID-TAG431] Expected publication date: TBC

Technology appraisal guidance In development

Falls - faller's clinics [ID103]

In development [GID-TAG375] Expected publication date: TBC

Technology appraisal guidance In development

Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

In development [GID-TAG414] Expected publication date: TBC

Technology appraisal guidance In development

Prostate cancer (prevention) - dutasteride [ID75]

In development [GID-TAG409] Expected publication date: TBC

Technology appraisal guidance In development

Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

In development [GID-TAG411] Expected publication date: TBC

Technology appraisal guidance In development

Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]

In development [GID-TAG337] Expected publication date: TBC

Technology appraisal guidance In development

Venous thromboembolism (VTE) - ximelagatran [ID396]

In development [GID-TAG378] Expected publication date: TBC

Technology appraisal guidance In development